Barclays PLC Raises Stake in Accuray Incorporated (NASDAQ:ARAY)

Barclays PLC lifted its position in Accuray Incorporated (NASDAQ:ARAY) by 97.9% in the third quarter, HoldingsChannel.com reports. The firm owned 210,819 shares of the medical equipment provider’s stock after purchasing an additional 104,310 shares during the quarter. Barclays PLC’s holdings in Accuray were worth $380,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ARAY. AQR Capital Management LLC purchased a new stake in Accuray in the 2nd quarter worth $30,000. US Bancorp DE grew its position in shares of Accuray by 1,087.7% during the third quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 16,316 shares in the last quarter. Caprock Group LLC bought a new stake in Accuray during the 3rd quarter valued at approximately $36,000. Intech Investment Management LLC purchased a new position in Accuray in the 3rd quarter worth approximately $41,000. Finally, Thrivent Financial for Lutherans bought a new position in Accuray in the 3rd quarter worth approximately $57,000. 64.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Trading Down 2.6 %

Shares of Accuray stock opened at $2.24 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. The firm has a market cap of $225.28 million, a price-to-earnings ratio of -13.18 and a beta of 1.47. Accuray Incorporated has a twelve month low of $1.40 and a twelve month high of $2.99. The business has a 50-day moving average price of $1.99 and a 200-day moving average price of $1.93.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The business had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same quarter in the previous year, the company posted ($0.03) EPS. Equities research analysts anticipate that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.